Denali Therapeutics Inc
DNLI17.440USD
+0.290+1.69%
Close 11/14, 16:00（ET）Quotes delayed by 15 min
2.56BMarket Cap
LossP/E TTM
More Details of Denali Therapeutics Inc Company
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Denali Therapeutics Inc Info
Ticker SymbolDNLI
Company nameDenali Therapeutics Inc
IPO dateDec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
Number of employees422
Security typeOrdinary Share
Fiscal year-endDec 08
Address161 Oyster Point Blvd.
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone16508668547
Websitehttps://www.denalitherapeutics.com
Ticker SymbolDNLI
IPO dateDec 08, 2017
CEODr. Ryan J. Watts, Ph.D.
Company Executives of Denali Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
765.12K
-0.38%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
+30.13%
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
765.12K
-0.38%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
+30.13%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Sep 29
Updated: Mon, Sep 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.15%
Baillie Gifford & Co.
7.90%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.05%
Biogen Inc
4.88%
Other
67.11%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.15%
Baillie Gifford & Co.
7.90%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.05%
Biogen Inc
4.88%
Other
67.11%
Shareholder Types
Shareholders
Proportion
Investment Advisor
55.46%
Investment Advisor/Hedge Fund
22.66%
Hedge Fund
11.87%
Sovereign Wealth Fund
6.34%
Individual Investor
4.92%
Corporation
4.88%
Research Firm
2.13%
Pension Fund
0.50%
Bank and Trust
0.36%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
524
145.41M
99.14%
-6.39M
2025Q2
524
153.05M
105.35%
-12.26M
2025Q1
537
151.12M
104.03%
-14.77M
2024Q4
523
145.56M
100.28%
-21.13M
2024Q3
518
152.07M
106.51%
-14.19M
2024Q2
504
147.18M
103.45%
-5.80M
2024Q1
491
145.33M
102.36%
+2.75M
2023Q4
499
138.06M
99.94%
+3.21M
2023Q3
492
132.50M
96.48%
-2.55M
2023Q2
504
131.32M
95.95%
-3.31M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
11.78M
8.06%
+10.98K
+0.09%
Jun 30, 2025
Baillie Gifford & Co.
11.96M
8.18%
-134.72K
-1.11%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.87M
6.75%
-168.55K
-1.68%
Jun 30, 2025
Fidelity Management & Research Company LLC
7.41M
5.07%
+125.57K
+1.72%
Jun 30, 2025
Biogen Inc
7.16M
4.89%
-5.60M
-43.89%
Oct 30, 2024
T. Rowe Price Associates, Inc.
6.46M
4.42%
+2.20M
+51.71%
Jun 30, 2025
Wellington Management Company, LLP
5.66M
3.87%
-5.74M
-50.35%
Jun 30, 2025
Temasek Holdings Pte. Ltd.
5.36M
3.66%
--
--
Jun 30, 2025
Capital Research Global Investors
4.75M
3.25%
-14.56K
-0.31%
Jun 30, 2025
State Street Investment Management (US)
4.52M
3.09%
+57.24K
+1.28%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
3.3%
ALPS Medical Breakthroughs ETF
1.26%
Global X Guru Index ETF
1.21%
Virtus LifeSci Biotech Clinical Trials ETF
0.7%
SPDR S&P Biotech ETF
0.68%
Direxion Daily S&P Biotech Bull 3X Shares
0.36%
Global X Aging Population ETF
0.33%
iShares Health Innovation Active ETF
0.25%
ProShares Ultra Nasdaq Biotechnology
0.22%
Invesco Nasdaq Biotechnology ETF
0.21%
View more
iShares Neuroscience and Healthcare ETF
Proportion3.3%
ALPS Medical Breakthroughs ETF
Proportion1.26%
Global X Guru Index ETF
Proportion1.21%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.7%
SPDR S&P Biotech ETF
Proportion0.68%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.36%
Global X Aging Population ETF
Proportion0.33%
iShares Health Innovation Active ETF
Proportion0.25%
ProShares Ultra Nasdaq Biotechnology
Proportion0.22%
Invesco Nasdaq Biotechnology ETF
Proportion0.21%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
